Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
A phase 2 trial of Sacituzumab govitecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Overview
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05186974 by Gilead Sciences, with 193 participants enrolled, started 2022-05-30 and due to reach its primary completion in 2027-03. Interventions recorded: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Pembrolizumab, Non-small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Novel Treatment Combinations in Patients With Lung Cancer
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin, Carboplatin.
- TrialStudy of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Cisplatin, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Cisplatin, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Cisplatin, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Cisplatin, Carboplatin, Pembrolizumab, Small-cell lung cancer.